| Study of AT-587 in Healthy Subjects (NCT07728487) | Atea Pharmaceuticals, Inc. | 2026-07-13 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) (NCT07272889) | Atea Pharmaceuticals, Inc. | 2025-12-04 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV (NCT07037277) | Atea Pharmaceuticals, Inc. | 2025-06-02 |
| Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir (NCT07007806) | Atea Pharmaceuticals, Inc. | 2025-05-09 |
| Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function (NCT06911320) | Atea Pharmaceuticals, Inc. | 2025-04-09 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin (NCT06921941) | Atea Pharmaceuticals, Inc. | 2025-04-08 |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV (NCT06868264) | Atea Pharmaceuticals, Inc. | 2025-04-07 |
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone (NCT07314346) | Atea Pharmaceuticals, Inc. | 2025-01-07 |
| Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir (NCT06204679) | Atea Pharmaceuticals, Inc. | 2023-12-14 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV (NCT05904470) | Atea Pharmaceuticals, Inc. | 2023-05-30 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects (NCT05905497) | Atea Pharmaceuticals, Inc. | 2023-04-26 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects (NCT05905484) | Atea Pharmaceuticals, Inc. | 2023-04-25 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir (NCT05731843) | Atea Pharmaceuticals, Inc. | 2023-01-30 |
| Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function (NCT05724693) | Atea Pharmaceuticals, Inc. | 2023-01-30 |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 (NCT05629962) | Atea Pharmaceuticals, Inc. | 2022-11-25 |
| Study of AT-527 in Subjects With Normal and Impaired Renal Function (NCT05618314) | Atea Pharmaceuticals, Inc. | 2022-10-17 |
| Study of AT-752 in Patients With Dengue Infection (NCT05466240) | Atea Pharmaceuticals, Inc. | 2022-04-29 |
| Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model (NCT05366439) | Atea Pharmaceuticals, Inc. | 2022-04-22 |
| Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal (NCT05256732) | Atea Pharmaceuticals, Inc. | 2022-02-22 |
| Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) (NCT05154123) | Atea Pharmaceuticals, Inc. | 2021-11-16 |
| Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) (NCT05137626) | Atea Pharmaceuticals, Inc. | 2021-11-03 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects (NCT04309734) | Atea Pharmaceuticals, Inc. | 2021-10-01 |
| Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) (NCT05004415) | Atea Pharmaceuticals, Inc. | 2021-07-28 |
| Bronchopulmonary PK of AT-527 (R07496998) (NCT04877769) | Atea Pharmaceuticals, Inc. | 2021-04-25 |
| Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) (NCT04865445) | Atea Pharmaceuticals, Inc. | 2021-04-22 |
| Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) (NCT04849299) | Atea Pharmaceuticals, Inc. | 2021-04-18 |
| Study of AT-752 in Healthy Subjects (NCT04722627) | Atea Pharmaceuticals, Inc. | 2021-03-09 |
| Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 (NCT04784000) | Atea Pharmaceuticals, Inc. | 2021-03-01 |
| Study of AT-527 in Healthy Subjects (R07496998) (NCT04711187) | Atea Pharmaceuticals, Inc. | 2020-11-02 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection (NCT04019717) | Atea Pharmaceuticals, Inc. | 2019-06-20 |